Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: WTDEC who wrote (16674)	3/7/1998 1:53:00 AM
From: Henry Niman	Respond to of 32384

At H&Q, LGND indicated that they were targeting thrombopoietin. Here's a definition of the growth factor: Thrombopoietin and biological effects. Thrombopoietin is a 80 KDa glycoprotein which contains two domains : the NH2 terminal domain which shows a 50 % homology with erythropoietin, contains the entire biological activity whereas the COOH terminal domain is involved in secretion and stabilisation of the molecule. Thrombopoietin has been isolated as the ligand of the c-mpl protooncogene. It is mainly synthesized by the kidney and the liver. Its plasmatic level is dependant upon the platelet mass by a mechasmism related to its clearance by platelets and megakaryocytes. Thombopoietin is the homeostatic regulator of platelet production and acts at all stages of megakaryocytopoiesis from the megakaryocyte progenitor to the platelet. However, thrombopoietin also acts on early stages of hematopoiesis, probably including true stem cells.